PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid-Reference-Cited by-同舟云学术

PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid

Published:2021-09 Issue:9 Volume:38 Page:1485-1496
ISSN:0724-8741
Container-title:Pharmaceutical Research
language:en
Short-container-title:Pharm Res

Author:

Balhara Ankit,Singh Saranjit^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s11095-021-03095-9.pdf

Reference61 articles.

1. Klein DJ, Boukouvala S, McDonagh EM, Shuldiner SR, Laurieri N, Thorn CF, et al. PharmGKB summary: isoniazid pathway, pharmacokinetics. Pharmacogenet Genomics. 2016;26(9):436–44.

2. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA, American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603–62.

3. Migliori GB, Zellweger JP, Abubakar I, Ibraim E, Caminero JA, De Vries G, D’Ambrosio L, et al. European Union standards for tuberculosis care. Eur Respir J. 2012;39:807–19.

4. World Health Organization. Treatment of Tuberculosis: Guidelines. 4th. Geneva: World Health Organization; 2010. Stop TB Initiative (World Health Organization).

5. Migliori GB, Raviglione MC, Schaberg T, Davies PD, Zellweger JP, Grzemska M, et al. Tuberculosis management in Europe. Task force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against tuberculosis and lung disease (IUATLD) Europe Region. Eur Respir J. 1999;14:978–92.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancy;Clinical and Translational Science;2023-09-15

3. Therapeutic drug monitoring in optimizing tuberculosis treatment outcomes: A review on the first-line four-drug standard treatment regimen;Saudi Journal of Clinical Pharmacy;2023

4. Potential drug–drug interactions among hospitalised TB patients;The International Journal of Tuberculosis and Lung Disease;2022-12-01

5. Pharmacometrics in tuberculosis: progress and opportunities;International Journal of Antimicrobial Agents;2022-09